Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis Moreá>
"Preeclampsia is a very exciting indication, and PSTI has the potential to completely change how we treat this insidious disease." (6/4/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>
Companies Commented On
- Abbott Laboratories
- Aethlon Medical Inc.
- Allscripts Healthcare Solutions, Inc.
- BioLife Solutions Inc.
- Biomerica Inc.
- Cryoport Inc.
- CytoSorbents Corp.
- FluoroPharma Medical Inc.
- HealthTronics Inc.
- iCAD, Inc.
- Interleukin Genetics Inc.
- Mela Sciences Inc.
- Merck & Co. Inc.
- OptimizeRx Corp.
- Pfizer Inc.
- SANUWAVE Health, Inc.
- Verisante Technology Inc.
- VolitionRx Ltd.
- Zecotek Photonics Inc.
Brian Marckx is the senior medical device/diagnostics analyst with Zacks Investment Research, He covers small- and micro-cap medical device and diagnostic companies with a focus on development-stage companies with novel and emerging technologies, as well as already established names still flying under the radar. Prior to joining Zacks, Marckx worked as a high-yield bond analyst on Wachovia Securities' institutional trading desks, where he specialized in the healthcare and industrials industries. Prior to that he was an analyst in corporate finance at First Union National Bank. Marckx has been quoted in The Wall Street Journal, Barron's, Bloomberg Businessweek and Kiplinger. His work has also been cited in various market studies and working papers including those from Massachusetts Institute of Technology, Deloitte & Touche, and Pharmaceutical Manufacturing. He graduated with a bachelor's degree in finance from St. John Fisher College, and received his master's degree in business administration from Wake Forest University. Marckx is also a Chartered Financial Analyst.
Micro-Cap Medtech with Explosive Upside Potential: Brian Marckx (12/19/13) Combine the complexity of genomic testing with the high risk inherent in micro-cap stocks, and you have investment opportunities that require exceptional diligence. The reward for understanding the value proposition of budding companies? The payoff can be enormous. In this interview with The Life Sciences Report, Senior Medical Device Analyst Brian Marckx of Zacks Investment Research has selected eight micro-cap names that could return triples, quads and more for investors willing to do their homework.
Eight Small-Cap Medtechs with Big Prospects: Brian Marckx (8/7/13) Small-cap medical technology has long been regarded as the ugly duckling of biotech. . .but think again. Brian Marckx of Zacks Small-Cap Research believes that the real gems of the medtech space complementŚand can even outshineŚsexier drug and surgical therapies. In this interview with The Life Sciences Report, Marckx makes a strong case for eight small- and micro-cap names that could bring home huge returns for investors.
"BLFS, which expects to benefit from the emerging field of regenerative medicine, set a new revenue record for the ninth straight quarter." (8/8/13) BioLife Solutions Inc. - The Life Sciences Report Interview with Brian Marckx Moreá>
"VRS makes a device called the Aura for the detection of skin cancer, which is a virtually untapped detection device market." (8/8/13) Verisante Technology Inc. - The Life Sciences Report Interview with Brian Marckx Moreá>
"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan Moreá>